Invention Grant
- Patent Title: Triazolopyridinyl compounds as kinase inhibitors
-
Application No.: US17503516Application Date: 2021-10-18
-
Publication No.: US11767322B2Publication Date: 2023-09-26
- Inventor: Guanglin Luo , Jie Chen , Carolyn Diane Dzierba , David B. Frennesson , Junqing Guo , Amy C. Hart , Xirui Hu , Michael C. Mertzman , Matthew Reiser Patton , Jianliang Shi , Steven H. Spergel , Brian Lee Venables , Yong-Jin Wu , Zili Xiao , Michael G. Yang
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Mary K. VanAtten
- Main IPC: C07D471/04
- IPC: C07D471/04
Abstract:
Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof,
are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
Public/Granted literature
- US20220119388A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS Public/Granted day:2022-04-21
Information query
